| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.80B | 28.68B | 27.61B | 24.86B | 21.97B | 19.10B |
| Gross Profit | 14.04B | 14.39B | 13.48B | 10.42B | 9.06B | 8.92B |
| EBITDA | 4.97B | 5.05B | 4.74B | 3.08B | 2.39B | 3.09B |
| Net Income | 3.48B | 3.70B | 3.69B | 2.40B | 1.62B | 1.99B |
Balance Sheet | ||||||
| Total Assets | 21.22B | 26.91B | 24.01B | 20.62B | 20.23B | 19.56B |
| Cash, Cash Equivalents and Short-Term Investments | 8.05B | 5.99B | 6.16B | 2.81B | 2.09B | 1.94B |
| Total Debt | 537.40M | 612.80M | 505.60M | 465.30M | 1.71B | 1.67B |
| Total Liabilities | 6.84B | 6.41B | 5.91B | 5.11B | 6.20B | 5.65B |
| Stockholders Equity | 14.38B | 20.50B | 18.08B | 15.49B | 14.44B | 14.29B |
Cash Flow | ||||||
| Free Cash Flow | 1.61B | 2.53B | 4.21B | 2.93B | 1.77B | 3.76B |
| Operating Cash Flow | 1.96B | 3.11B | 4.58B | 3.29B | 2.03B | 4.02B |
| Investing Cash Flow | -1.17B | -1.61B | -3.44B | -482.90M | -317.13M | -1.29B |
| Financing Cash Flow | -1.44B | -1.57B | -1.35B | -2.51B | -1.67B | -2.16B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹128.49B | -90.62 | ― | 0.28% | 14.55% | -20.61% | |
63 Neutral | ₹136.80B | 31.27 | ― | 0.52% | 30.11% | 23.22% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ₹80.60B | 31.99 | ― | 1.24% | 1.62% | -7.32% | |
61 Neutral | ₹55.50B | 46.45 | ― | 0.45% | 10.82% | -8.21% | |
60 Neutral | ₹63.50B | 30.80 | ― | 1.07% | 22.63% | -8.57% | |
54 Neutral | ₹87.54B | 46.47 | ― | ― | 10.59% | 67.55% |
Jyothy Labs Limited has scheduled an investor and analyst meeting with Mirabilis Investment Trust on March 12, 2026, to be held as a one-on-one interaction. The company has clarified that no unpublished price-sensitive information will be shared during this engagement and has directed stakeholders to its latest investor presentation available on its website, indicating a routine investor relations outreach rather than a strategic or operational shift.
Jyothy Labs Limited has notified stock exchanges about a scheduled investor and analyst meeting with Eternity Capital on March 11, 2026. The company clarified that the interaction will not involve sharing any unpublished price-sensitive information and directed stakeholders to its latest investor presentation available on its website, underscoring its adherence to disclosure norms and ongoing investor engagement.
The announcement signals continued effort by Jyothy Labs to maintain transparent communication with the investment community while complying with regulatory requirements. For shareholders and market participants, the meeting represents part of the company’s regular outreach rather than a disclosure of new financial or strategic information.
Jyothy Labs Limited has submitted to the BSE and the National Stock Exchange a copy of its investor presentation detailing the company’s performance for the quarter and nine months ended December 31, 2025. The presentation, which is also available on the company’s website, is intended to update and inform investors about its recent financial and operational results, reinforcing disclosure standards and transparency for market participants.
By formally disseminating this performance update to both major Indian exchanges, Jyothy Labs underscores its compliance with listing requirements and its engagement with the investor community. The move ensures that shareholders and potential investors have timely access to key performance information, supporting informed decision-making and aligning with best practices in corporate governance and investor relations.